GlassScriptPhysician profile
Kelly Hogan
NPI 1861123564
$1,985.92
in general payments reported to CMS, 2019-2025
27 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $255 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $353.01 | 2025 | Evenity, Prolia |
| Lilly USA, LLC | $347.52 | 2025 | Jardiance, Mounjaro, Zepbound |
| Nevro Corp. | $197.50 | 2024 | Senza |
| Abbott Laboratories | $147.95 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $137.18 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $89.97 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $83.59 | 2025 | Korlym |
| Sequel Med Tech, LLC | $74.78 | 2025 | Twiist |
| Abbvie INC. | $65.48 | 2025 | |
| Amneal Pharmaceuticals LLC | $53.28 | 2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $50.13 | 2025 | |
| Novo Nordisk INC | $48.36 | 2025 | Ozempic, Wegovy |
| Radius Health, INC. | $41.66 | 2025 | Tymlos |
| Neurocrine Biosciences, INC. | $39.04 | 2025 | |
| Averitas Pharma INC. | $31.77 | 2024-2025 | Qutenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.52 | 2024-2025 | |
| Glaxosmithkline, LLC. | $27.28 | 2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $25.10 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.47 | 2025 | Jardiance |
| Medtronic, INC. | $17.40 | 2025 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $16.89 | 2025 | |
| Tolmar, INC. | $16.71 | 2025 | Jatenzo |
| Evoke Pharma, INC. | $16.65 | 2025 | |
| Mannkind Corporation | $16.53 | 2025 | |
| Currax Pharmaceuticals LLC | $15.21 | 2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $13.65 | 2025 | Farxiga |
| Cequr Corporation | $12.29 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.